Inactive Instrument

Highlights Ambrx Biopharma Inc.

Equities

AMAM

US6418711080

Highlights

Unlock all the news: Be the first to know and act before the market!

Johnson & Johnson Completes Ambrx Acquisition	07/03	MT
J&J: completes $2 billion acquisition of Ambrx Biopharma	07/03	CF
Johnson & Johnson completed the acquisition of Ambrx Biopharma Inc. from a group of shareholders.	07/03	CI
Ambrx Biopharma Shareholders Approve Johnson & Johnson Acquisition Deal	07/03	MT
J&J's Acquisition of Ambrx Biopharma Completes Hart-Scott-Rodino Waiting Period	23/02	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	23/01	DJ
North American Morning Briefing : Focus Fixed on -2-	11/01	DJ
Global markets live: Boeing, GSK, Hays, Shell, Eli Lilly...	09/01
Health Care Up as Merger Wave Continues -- Health Care Roundup	09/01	DJ
Trending : Johnson & Johnson and Merck & Co. Announce Acquisitions	09/01	DJ
Drugmakers kick off industry conference with two cancer deals	08/01	RE
Johnson & Johnson Strikes $2 Billion Deal to Take Ambrx Biopharma Private	08/01	MT
Ambrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & Johnson	08/01	DJ
Johnson & Johnson Agrees to Acquire Ambrx Biopharma for $28 Per Share; Ambrx Shares Soar Pre-Bell	08/01	MT
J&J: acquisition of Ambrx for $2 billion	08/01	CF
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion	08/01	DJ
Johnson & Johnson to Acquire Ambrx Biopharma in $2 Billion All-Cash Deal	08/01	MT
J&J to buy cancer therapy developer Ambrx for $2 bln	08/01	RE
Johnson & Johnson entered into a definitive agreement to acquire Ambrx Biopharma Inc. for $1.8 billion.	08/01	CI
Ambrx Biopharma to Join Nasdaq Biotechnology Index	14/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ambrx Biopharma Inc.

Equities

AMAM

US6418711080

Highlights

Filters